Disclosure of Voting Results and Scrutinizer''s Report for 32nd Annual General Meeting of the Company held on Monday, 29th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries Ltd held its 32nd AGM on 29th September 2025, where all 7 resolutions were passed unanimously with 100% votes in favour. The resolutions included adoption of audited financial statements for FY ended 31st March 2025, re-appointment of Mrs. Abha Agrawal as director (retiring by rotation), appointment of statutory auditor for FY 2025-26, and re-appointment of Mr. Arvind Vilasrao Sapkal as Non-executive Independent Director via special resolution. Additionally, M/s Meenu Maheshwari & Associates was appointed as secretarial auditor, and related party transactions with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited were approved. Of the 5,379 total shareholders on record date, 45 members participated representing 15,58,051 shares, with no votes cast against any resolution. The scrutinizer Meenu Maheshwari confirmed all resolutions passed with requisite majority.
This is a routine regulatory disclosure confirming successful completion of the AGM. No negative signals — all resolutions passed unanimously, indicating strong shareholder alignment with management proposals. The approval of related party transactions is standard governance compliance and unlikely to materially impact the stock price.